ZipBio is at the forefront of therapeutic innovation, leveraging generative AI to create novel therapeutic molecules that address significant unmet medical needs. The company focuses on developing de novo genes and proteins, which allows them to condense complex biological functions into compact, highly effective therapeutic agents. Their proprietary COMPACT™ platform is designed to compress intricate biological structures into smaller, more efficient proteins while maintaining their full functionality. This technology aims to optimize the delivery and effectiveness of therapies, particularly for challenging diseases that have limited treatment options.

The company's pipeline is particularly concentrated on ophthalmology, where they are developing several preclinical programs aimed at transforming treatment standards for prevalent ocular diseases. ZipBio's approach involves creating multifunctional therapeutic compounds that can target multiple pathways with a single molecule, addressing the complexities of ocular anatomy and the invasive nature of current delivery methods. By focusing on compact, multifunctional designs, ZipBio is poised to redefine therapeutic strategies in ophthalmology and beyond, with plans to enter clinical trials for their lead program in 2026.

United States

ZipBio is a biotech startup revolutionizing AI drug discovery with our cutting-edge protein design and drug discovery platform. We specialize in compressing biology to accelerate therapeutic innovation.

ZipBio

Company Details